semaglutide and fda The approved a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 Novo asks FDA to bar

Stapled -helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Two pathways do open Part D coverage for GLP-1 receptor agonists in 2026, but both require a non-weight-loss diagnosis

Equity means ensuring that everyone has the same chance to live a healthy life

Three years later, a significant amount of that plaque is gone

Some people need [their] bodies jumpstarted, some have diabetes, theres lots of reasons

The clinic describes its partners only in general terms, as state-licensed 503A compounding pharmacies, and would not name a specific facility when we asked support directly